At the J.P. Morgan Health Care conference, the future outlook for GLP-1 drugs used to treat obesity was a key focus, ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 463.56% and ...

Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed by double ...

Weight-loss drug Wegovy to begin sales in Korea after 16-month wait Novo Nordisk Pharma debuts smart sensor for insulin pens Son of Hanmi founder ousts mother as co-CEO as family feud continues 'I can ...

Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. LLY’s ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...